Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jun 8;76(11):2010-2013.
doi: 10.1093/cid/ciad107.

Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)

Emma M Kileel  1 , Carlos D Malvestutto  2 , Janet Lo  1 , Kathleen V Fitch  1 , Carl J Fichtenbaum  3 , Judith A Aberg  4 , Markella V Zanni  1 , Esteban Martinez  5 , Nwora Lance Okeke  6   7 , Princy Kumar  8 , Esau Joao  9 , Sara H Bares  10 , Daniel Berrner  11 , Marek Smieja  12 , Jhoanna C Roa  13 , Sara McCallum  1 , Pamela S Douglas  14 , Heather J Ribaudo  15 , Steven K Grinspoon  1
Affiliations
Randomized Controlled Trial

Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)

Emma M Kileel et al. Clin Infect Dis. .

Abstract

Over 2-years of follow-up, integrase strand transfer inhibitor (INSTI)-use was associated with weight gain among those on an INSTI <2 years at entry (+0.27 kg/m2/year; 95% confidence interval [CI], .22 to .33 vs +0.17 kg/m2/year; 95% CI, .12 to .23; P = .01), but not those on an entry INSTI >2 years.

Keywords: HIV; body mass index (BMI); integrase strand transfer inhibitors (INSTIs); weight.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. C. D. M. reports institutional research grants from Lilly and personal fees from ViiV Healthcare and Gilead Sciences for participation in advisory board meetings outside the submitted work. J. L. reports consulting fees from ViiV Healthcare and Gilead Sciences, Inc, as well as investigator-initiated research grant support from ViiV Healthcare related to this work. C. J. F. reports grant support through their institution from Gilead Sciences, ViiV Healthcare, GSK, Janssen, AbbVie, Merck, Amgen, and Cytodyn, outside the submitted work; personal fees from Theratechnologies and ViiV Healthcare for consulting and participation on an advisory board unrelated to Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE); and a role as chair on the data and safety monitoring board (DSMB) for the Intrepid Study, outside the submitted work. J. A. A. reports institutional research support for clinical trials from Atea, Emergent Biosolutions, Frontier Technologies, Gilead Sciences, GSK, Janssen, Merck, Pfizer, Regeneron, and ViiV Healthcare; personal fees for participation on advisory boards from GSK/ViiV Healthcare and Merck; and participation on a DSMB from Kintor, all outside the submitted work. M. V. Z. reports grant support through their institution from NIH/NIAID and Gilead Sciences, Inc, relevant to the conduct of the study, as well as grants from NIH/NIAID and NIH/NHLBI, outside the submitted work; unpaid participation on a DSMB for NIH-funded studies; and support for meetings and/or travel from Conference on Retroviruses and Opportunistic Infections (CROI) and the International Workshop for HIV and Women from the conference organizing committee as an abstract reviewer and/or speaker. E. M. reports consulting fees and honoraria for lectures from Gilead Sciences, ViiV Healthcare, Janssen, and MSD; advisory board participation for ViiV Healthcare and MSD; and that their institution has received research grants from Gilead, Janssen, MSD, Theratechnologies, and ViiV Healthcare, unrelated to the submitted work. N. L. O. reports grants from NIH/NHLBI during the conduct of the study and consulting fees from Gilead Sciences unrelated to the submitted work. P. K. serves as a consultant and receives research funding from ViiV Healthcare, Merck, Theratechnologies, and Gilead and owns stock in Pfizer, Gilead, Merck, GSK, and Moderna. S. H. B. reports serving as a scientific advisor to Gilead Sciences including payment for expert testimony and research grants to their institution from Gilead Sciences, ViiV Healthcare, and Janssen unrelated to the submitted work. J. C. R. reports work supported by NIAID of the NIH. H. J. R. reports grants from NIH/NHLBI and Kowa Pharmaceuticals America, Inc, during the conduct of the study as well as grants from NIH/NIAID, NIH/NHLBI, NIH/National Institute of Diabetes and Digestive and Kidney Diseases, and NIH/National Institute on Aging outside the submitted work. S. K. G. reports grants from NIH, Kowa Pharmaceuticals America, Inc, Gilead Sciences, and ViiV Healthcare during the conduct of the study; personal consulting fees from Theratechnologies, ViiV Healthcare, and Marathon Asset Management outside the submitted work; and participation on the Marathon Asset Management Scientific Advisory Board. All remaining authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Change in BMI per year over follow-up in REPRIEVE, stratified by duration of entry to ART regimen. Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; INSTI, integrase strand transfer inhibitor; REPRIEVE, Randomized Trial to Prevent Vascular Events in HIV. *P values represent P value for 3-way interaction between ART duration, year, and INTSI use.
See this image and copyright information in PMC

References

    1. Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis 2020; 71:1379–89. - PMC - PubMed
    1. Venter WDF, Bosch B, Sokhela S, et al. Final week 192 results from the ADVANCE trial: first-line TAF/FTC/DTG, TDF/FTC/DTG vs TDF/FTC/EFV. 2022. Available at: https://programme.aids2022.org/Abstract/Abstract/?abstractid=12600#:∼:te.... Accessed 14 December 2022.
    1. Grinspoon SK, Fitch KV, Overton ET, et al. Rationale and design of the randomized trial to prevent vascular events in HIV (REPRIEVE). Am Heart J 2019; 212:23–35. - PMC - PubMed
    1. Grinspoon SK, Douglas PS, Hoffmann U, Ribaudo HJ. Leveraging a landmark trial of primary cardiovascular disease prevention in human immunodeficiency virus: introduction from the REPRIEVE coprincipal investigators. J Infect Dis 2020; 222(Suppl_1):S1–7. - PMC - PubMed
    1. Kileel EM, Lo J, Malvestutto C, et al. Assessment of obesity and cardiometabolic status by integrase inhibitor use in REPRIEVE: a propensity-weighted analysis of a multinational primary cardiovascular prevention cohort of people with human immunodeficiency virus. Open Forum Infect Dis 2021; 8:ofab537. doi: 10.1093/ofid/ofab537. - DOI - PMC - PubMed

Publication types